Operaciones Better Therapeutics, Inc. - BTTX CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Diferencial | 0.0562 | ||||||||
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.025457% | ||||||||
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | 0.003235% | ||||||||
Horario tarifa nocturna | 21:00 (UTC) | ||||||||
Cantidad comercializada mínima | 1 | ||||||||
Divisa | USD | ||||||||
Margen | 20% | ||||||||
Mercado de valores | United States of America | ||||||||
Comisión por operación | 0% |
*Information provided by Capital.com
Cierre previo* | 0.6683 |
Abrir* | 0.6671 |
Cambio de 1 año* | -67.3% |
Rango del día* | 0.6486 - 0.7027 |
Rango de 52 semanas | 0.59-2.80 |
Volumen medio (10 días) | 135.87K |
Volumen medio (3 meses) | 2.90M |
Capitalización de mercado | 21.89M |
Ratio P/E | -100.00K |
Acciones en circulación | 31.73M |
Ingresos | N/A |
EPS | -1.67 |
Dividendo (Rendimiento %) | N/A |
Beta | -100.00K |
Próxima fecha de resultados | Aug 9, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Cierre | Change | Change (%) | Apertura | High | Low |
---|---|---|---|---|---|---|
May 26, 2023 | 0.6830 | 0.0159 | 2.38% | 0.6671 | 0.7263 | 0.6480 |
May 25, 2023 | 0.6683 | -0.0257 | -3.70% | 0.6940 | 0.7422 | 0.6483 |
May 24, 2023 | 0.7168 | -0.0290 | -3.89% | 0.7458 | 0.7459 | 0.6924 |
May 23, 2023 | 0.7507 | 0.0054 | 0.72% | 0.7453 | 0.7651 | 0.7453 |
May 22, 2023 | 0.7555 | 0.0201 | 2.73% | 0.7354 | 0.7942 | 0.7354 |
May 19, 2023 | 0.7564 | 0.0013 | 0.17% | 0.7551 | 0.7747 | 0.7540 |
May 18, 2023 | 0.7554 | -0.0015 | -0.20% | 0.7569 | 0.7845 | 0.7356 |
May 17, 2023 | 0.7582 | 0.0126 | 1.69% | 0.7456 | 0.7797 | 0.7456 |
May 16, 2023 | 0.7620 | -0.0388 | -4.85% | 0.8008 | 0.8037 | 0.7260 |
May 15, 2023 | 0.7457 | -0.0580 | -7.22% | 0.8037 | 0.8136 | 0.7359 |
May 12, 2023 | 0.7470 | 0.0310 | 4.33% | 0.7160 | 0.7749 | 0.7159 |
May 11, 2023 | 0.7555 | -0.0823 | -9.82% | 0.8378 | 0.8571 | 0.7257 |
May 10, 2023 | 0.8349 | 0.0215 | 2.64% | 0.8134 | 0.8716 | 0.7544 |
May 9, 2023 | 0.8039 | 0.0391 | 5.11% | 0.7648 | 0.8137 | 0.7262 |
May 8, 2023 | 0.7746 | -0.1165 | -13.07% | 0.8911 | 0.8911 | 0.6907 |
May 5, 2023 | 0.9005 | 0.0042 | 0.47% | 0.8963 | 0.9298 | 0.8905 |
May 4, 2023 | 0.9297 | -0.1353 | -12.70% | 1.0650 | 1.0653 | 0.8708 |
May 3, 2023 | 1.0750 | 0.0017 | 0.16% | 1.0733 | 1.1041 | 1.0635 |
May 2, 2023 | 1.0944 | 0.0095 | 0.88% | 1.0849 | 1.1233 | 1.0652 |
May 1, 2023 | 1.0943 | -0.0281 | -2.50% | 1.1224 | 1.1332 | 1.0741 |
Better Therapeutics, Inc. Events
Hora (UTC) (UTC) | País | Evento |
---|---|---|
Wednesday, August 9, 2023 | ||
Hora (UTC) (UTC) 20:00 | País US
| Evento Q2 2023 Better Therapeutics Inc Earnings Release Q2 2023 Better Therapeutics Inc Earnings ReleaseForecast -Previous - |
Monday, November 13, 2023 | ||
Hora (UTC) (UTC) 21:00 | País US
| Evento Q3 2023 Better Therapeutics Inc Earnings Release Q3 2023 Better Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Anual
- Trimestral
2022 | 2021 | 2020 | |
---|---|---|---|
Ingresos totales | 0 | 0 | 0 |
Gastos totales de explotación | 38.262 | 40.303 | 0.00169 |
Other Operating Expenses, Total | 0.00169 | ||
Ingresos de explotación | -38.262 | -40.303 | -0.00169 |
Ingresos netos antes de impuestos | -39.753 | -40.488 | -0.00169 |
Ingresos netos después de impuestos | -39.76 | -40.335 | -0.00169 |
Beneficio neto antes de partidas extra. Elementos | -39.76 | -40.335 | -0.00169 |
Ingresos netos | -39.76 | -40.335 | -0.00169 |
Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -39.76 | -40.335 | -0.00169 |
Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -39.76 | -40.335 | -0.00169 |
Beneficio neto diluido | -39.76 | -40.335 | -0.00169 |
Promedio ponderado de acciones diluidas | 23.5578 | 23.6027 | 7.5575 |
BPA diluido sin partidas extraordinarias | -1.68776 | -1.70891 | -0.00022 |
Dividends per Share - Common Stock Primary Issue | 0 | ||
BPA normalizado diluido | -1.68776 | -1.4406 | -0.00022 |
Gastos de venta/general/administración Gastos, total | 21.822 | 11.124 | |
Investigación y desarrollo | 16.44 | 19.436 | |
Gastos (ingresos) extraordinarios | 0 | 9.743 | |
Ingresos por intereses (gastos), netos No operativos | -1.491 | -0.185 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Ingresos totales | 0 | 0 | 0 | 0 | 0 |
Gastos totales de explotación | 8.925 | 8.322 | 10.996 | 9.599 | 9.345 |
Other Operating Expenses, Total | |||||
Ingresos de explotación | -8.925 | -8.322 | -10.996 | -9.599 | -9.345 |
Ingresos por intereses (gastos), netos No operativos | -0.431 | -0.439 | -0.406 | -0.329 | -0.317 |
Ingresos netos antes de impuestos | -9.356 | -8.761 | -11.402 | -9.928 | -9.662 |
Ingresos netos después de impuestos | -9.357 | -8.765 | -11.405 | -9.928 | -9.662 |
Beneficio neto antes de partidas extra. Elementos | -9.357 | -8.765 | -11.405 | -9.928 | -9.662 |
Ingresos netos | -9.357 | -8.765 | -11.405 | -9.928 | -9.662 |
Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -9.357 | -8.765 | -11.405 | -9.928 | -9.662 |
Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -9.357 | -8.765 | -11.405 | -9.928 | -9.662 |
Beneficio neto diluido | -9.357 | -8.765 | -11.405 | -9.928 | -9.662 |
Promedio ponderado de acciones diluidas | 23.8266 | 23.6315 | 23.6931 | 23.593 | 23.4132 |
BPA diluido sin partidas extraordinarias | -0.39271 | -0.3709 | -0.48136 | -0.4208 | -0.41267 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
BPA normalizado diluido | -0.39271 | -0.3709 | -0.48136 | -0.4208 | -0.41267 |
Gastos de venta/general/administración Gastos, total | 5.536 | 5.273 | 5.519 | 5.358 | 5.672 |
Investigación y desarrollo | 3.389 | 3.049 | 5.477 | 4.241 | 3.673 |
Gastos (ingresos) extraordinarios | 0 | 0 | 0 | 0 |
- Anual
- Trimestral
2022 | 2021 | 2020 | |
---|---|---|---|
Total Activo Corriente | 18.446 | 45.251 | 0.08666 |
Efectivo e inversiones a corto plazo | 15.74 | 40.566 | 0.02476 |
Cash | 0.02476 | ||
Other Current Assets, Total | 0.21 | 0.276 | 0.06189 |
Total Assets | 22.943 | 50.958 | 0.08666 |
Total Current Liabilities | 13.494 | 4.733 | 0.06334 |
Accrued Expenses | 5.927 | 3.21 | 0.00145 |
Notes Payable/Short Term Debt | 0 | 0 | 0.06189 |
Total Liabilities | 23.842 | 14.238 | 0.06334 |
Total Long Term Debt | 10.348 | 9.505 | 0 |
Total Equity | -0.899 | 36.72 | 0.02331 |
Common Stock | 0.002 | 0.002 | 0.00014 |
Additional Paid-In Capital | 110.602 | 108.461 | 0.02486 |
Retained Earnings (Accumulated Deficit) | -111.503 | -71.743 | -0.00169 |
Total Liabilities & Shareholders’ Equity | 22.943 | 50.958 | 0.08666 |
Total Common Shares Outstanding | 23.851 | 23.6027 | 7.5575 |
Efectivo y Equivalentes | 15.74 | 40.566 | |
Prepaid Expenses | 2.496 | 4.409 | |
Property/Plant/Equipment, Total - Net | 0.121 | 0.082 | |
Intangibles, Net | 3.888 | 5.077 | |
Other Long Term Assets, Total | 0.488 | 0.548 | |
Accounts Payable | 3.035 | 1.523 | |
Long Term Debt | 10.348 | 9.505 | |
Property/Plant/Equipment, Total - Gross | 0.178 | ||
Accumulated Depreciation, Total | -0.057 | ||
Current Port. of LT Debt/Capital Leases | 4.532 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Activo Corriente | 8.442 | 18.446 | 23.49 | 32.137 | 35.179 |
Efectivo e inversiones a corto plazo | 6.068 | 15.74 | 22.305 | 29.685 | 31.673 |
Cash | |||||
Prepaid Expenses | 1.968 | 2.496 | 1.123 | 2.38 | 3.242 |
Total Assets | 12.808 | 22.943 | 28.221 | 37.103 | 40.291 |
Long Term Investments | |||||
Other Long Term Assets, Total | 0.483 | 0.488 | 0.488 | 0.487 | 0.488 |
Total Current Liabilities | 13.64 | 13.494 | 9.312 | 6.141 | 3.567 |
Accrued Expenses | 5.588 | 5.927 | 4.928 | 3.27 | 2.528 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 22.641 | 23.842 | 20.969 | 19.049 | 12.866 |
Total Long Term Debt | 9.001 | 10.348 | 11.657 | 12.908 | 9.299 |
Other Liabilities, Total | |||||
Total Equity | -9.833 | -0.899 | 7.252 | 18.054 | 27.425 |
Common Stock | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 |
Additional Paid-In Capital | 111.025 | 110.602 | 109.988 | 109.385 | 108.828 |
Retained Earnings (Accumulated Deficit) | -120.86 | -111.503 | -102.738 | -91.333 | -81.405 |
Total Liabilities & Shareholders’ Equity | 12.808 | 22.943 | 28.221 | 37.103 | 40.291 |
Total Common Shares Outstanding | 23.8523 | 23.851 | 23.7441 | 23.733 | 23.6086 |
Payable/Accrued | |||||
Efectivo y Equivalentes | 6.068 | 15.74 | 22.305 | 29.685 | 31.673 |
Other Current Assets, Total | 0.406 | 0.21 | 0.062 | 0.072 | 0.264 |
Property/Plant/Equipment, Total - Net | 0.131 | 0.121 | 0.122 | 0.115 | 0.098 |
Intangibles, Net | 3.752 | 3.888 | 4.121 | 4.364 | 4.526 |
Accounts Payable | 2.513 | 3.035 | 1.255 | 1.088 | 0.735 |
Long Term Debt | 9.001 | 10.348 | 11.657 | 12.908 | 9.299 |
Current Port. of LT Debt/Capital Leases | 5.539 | 4.532 | 3.129 | 1.783 | 0.304 |
- Anual
- Trimestral
2022 | 2021 | 2020 | |
---|---|---|---|
Ingresos netos/Línea de salida | -39.76 | -40.335 | -0.00169 |
Efectivo de actividades de explotación | -28.93 | -30.818 | -0.00024 |
Cambios en el capital circulante | 6.268 | -2.339 | 0.00145 |
Efectivo procedente de actividades de financiación | 5.284 | 72.332 | 0.025 |
Elementos de flujo de caja de financiación | 0 | 62.331 | -0.06189 |
Emisión (retiro) de acciones, neto | 0.284 | 0.001 | 0.025 |
Emisión (amortización) de deuda, neta | 5 | 10 | 0.06189 |
Variación neta de la tesorería | -24.826 | 40.443 | 0.02476 |
Efectivo de actividades de explotación | 2.729 | 1.619 | |
Deferred Taxes | 0 | -0.152 | |
Partidas no monetarias | 1.833 | 10.389 | |
Intereses pagados en efectivo | 1.325 | 0.085 | |
Efectivo de actividades de inversión | -1.18 | -1.071 | |
Gastos de capital | -1.18 | -1.071 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -9.357 | -39.76 | -30.995 | -19.59 | -9.662 |
Cash From Operating Activities | -8.716 | -28.93 | -22.593 | -15.57 | -8.855 |
Non-Cash Items | 0.41 | 1.833 | 1.384 | 0.787 | 0.375 |
Changes in Working Capital | -0.524 | 6.268 | 5.01 | 1.919 | -0.231 |
Cash From Investing Activities | -0.521 | -1.18 | -0.82 | -0.457 | -0.039 |
Other Investing Cash Flow Items, Total | |||||
Cash From Financing Activities | -0.435 | 5.284 | 5.152 | 5.146 | 0.001 |
Financing Cash Flow Items | 0 | 0 | 0 | 0 | |
Issuance (Retirement) of Stock, Net | 0 | 0.284 | 0.152 | 0.146 | 0.001 |
Issuance (Retirement) of Debt, Net | -0.435 | 5 | 5 | 5 | |
Net Change in Cash | -9.672 | -24.826 | -18.261 | -10.881 | -8.893 |
Cash From Operating Activities | 0.755 | 2.729 | 2.008 | 1.314 | 0.663 |
Deferred Taxes | 0 | 0 | 0 | 0 | |
Cash Interest Paid | 0.495 | 1.325 | 0.87 | 0.462 | 0.219 |
Capital Expenditures | -0.521 | -1.18 | -0.82 | -0.457 | -0.039 |
Cash Taxes Paid | 0 |
Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
---|---|---|---|---|---|---|
Perry (David P) | Individual Investor | 53.1606 | 16868581 | 6404566 | 2023-04-12 | LOW |
Georgianna Maule-Ffinch 2015 Trust | Individual Investor | 11.4598 | 3636364 | 3636364 | 2023-04-10 | |
Appelbaum (Kevin J) | Individual Investor | 7.5847 | 2406719 | -6250 | 2023-04-10 | LOW |
Mountain Crest Capital LLC | Corporation | 4.375 | 1388250 | 0 | 2023-04-10 | LOW |
Farallon Capital Management, L.L.C. | Hedge Fund | 2.203 | 699042 | -114514 | 2023-03-31 | MED |
Armanino (Andrew J) | Individual Investor | 1.4739 | 467692 | 303030 | 2023-04-10 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 1.3818 | 438479 | 3700 | 2023-03-31 | LOW |
Parker (Geoffrey M) | Individual Investor | 1.2491 | 396363 | 303030 | 2023-04-10 | LOW |
Maule-Ffinch (Georgianna) | Individual Investor | 0.9238 | 293150 | 0 | 2023-04-10 | LOW |
Karbe (Frank L) | Individual Investor | 0.9216 | 292424 | 242424 | 2023-04-10 | MED |
Berman Mark A | Individual Investor | 0.7309 | 231939 | 0 | 2023-04-10 | LOW |
Carmona (Richard H. M.D.) | Individual Investor | 0.4841 | 153619 | 0 | 2023-04-10 | LOW |
Wynholds (Kristin) | Individual Investor | 0.3114 | 98819 | 0 | 2023-04-10 | LOW |
Heinen (Mark) | Individual Investor | 0.2773 | 88004 | 1 | 2023-04-10 | MED |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.2523 | 80054 | 798 | 2023-03-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.18 | 57109 | 0 | 2023-03-31 | LOW |
Susquehanna International Group, LLP | Investment Advisor | 0.1497 | 47516 | -6473 | 2023-03-31 | MED |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.1424 | 45200 | 0 | 2023-03-31 | LOW |
Zamirowski (Justin) | Individual Investor | 0.1163 | 36913 | 36913 | 2022-05-27 | |
Millennium Management LLC | Hedge Fund | 0.0837 | 26556 | 14932 | 2023-03-31 | HIGH |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group530K+
Traders
87K+
Clientes activos mensualmente
$46M+
Volumen mensual de inversión
$31M+
Retiros por mes
Calculadora de trading
Calcula tus P&L hipotéticas en el supuesto de haber abierto una operación con CFD en una fecha determinada (selecciona una fecha) y haberla cerrado en otra fecha (selecciona una fecha).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Better Therapeutics, Inc. Company profile
Sobre Better Therapeutics Inc
Better Therapeutics, Inc, anteriormente Mountain Crest Acquisition Corp II, se dedica a ofrecer una plataforma terapéutica digital de prescripción para tratar enfermedades cardiometabólicas. La empresa crea tratamientos para revertir la progresión de la enfermedad, mejorar la calidad de vida e informar sobre las decisiones clínicas. Construye terapias digitales de prescripción que ofrecen un nuevo tipo de terapia conductual y crean mecanismos de retroalimentación utilizando datos monitorizados a distancia y generados por el paciente. Su proyecto de desarrollo clínico incluye BT-001, BT-002, BT-003, BT-004 y BT-005. Está evaluando el BT-001 en un estudio fundamental como tratamiento prescrito bajo supervisión médica para personas con diabetes de tipo 2 no controlada. La empresa desarrolla la Terapia Cognitiva Conductual Nutricional (TCC Nutricional), que es una forma novedosa de terapia conductual en desarrollo para el tratamiento de pacientes con diabetes de tipo 2 y otras enfermedades cardiometabólicas.
El precio actual de la acción Better Therapeutics, Inc. en tiempo real es 0.68 USD. El gráfico de la acción permite a los inversores comprender mejor el rendimiento y el precio de la acción y tomar decisiones informadas al negociar acciones y CFD.
Descubra más acciones con gráficos, datos vitales y actualizaciones de precios en tiempo real: iShares Trust - iShares 5-10 Year Investment Grade Corporate Bond ETF, Gilead Sciences, CBRE Group, Inc., Air Transport Services, Mitsui Chemicals, Inc. y Advanced Energy Industries, Inc.. Para obtener más información, consulte los perfiles de las empresas en Capital.com.
Industry: | Biotechnology & Medical Research (NEC) |
548 Market St. #49404
SAN FRANCISCO
CALIFORNIA 94101
US
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 530.000 traders de todo el mundo que eligen operar con Capital.com